The demo realized the two its Key endpoints, with semaglutide 2.four mg demonstrating statistically major and exceptional enhancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH as co